Targeting specific proteins to improve cancer treatment
Cyclin Dependent Kinases as Epigenetic Therapy Targets
This study is looking for new ways to help treat myeloid leukemias by finding drugs that can change how cancer cells behave, making them more responsive to current treatments and possibly helping the immune system fight the cancer better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Coriell Institute for Medical Research NIH-funded |
| Lab location | 1 site (Camden, United States) |
| Project ID | NIH-10886781 on NIH RePORTER |
What this research studies
This research focuses on developing new epigenetic therapies that can reprogram gene expression in cancer cells, particularly in myeloid leukemias. By screening for drugs that inhibit a protein called CDK9, the researchers aim to activate silenced genes and suppress oncogenes, potentially enhancing the effectiveness of existing cancer treatments. The approach involves using live cell assays to identify compounds that can achieve significant changes in gene expression, which may also help to boost the immune response against tumors. This innovative strategy could lead to more effective cancer therapies by combining gene regulation with immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myeloid leukemias or other cancers that may benefit from epigenetic therapies.
Not a fit: Patients with cancers that do not involve the targeted pathways or those who are not responsive to epigenetic therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve outcomes for patients with certain types of cancer.
How similar studies have performed: Other research has shown promising results with similar approaches targeting cyclin-dependent kinases in cancer therapy, indicating potential for success.
Where this research is happening
Camden, United States
- Coriell Institute for Medical Research — Camden, United States (Active)
Researchers
- Principal investigator: Issa, Jean-Pierre J. — Coriell Institute for Medical Research
- Study coordinator: Issa, Jean-Pierre J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.